Lanadelumab

Plasma Kallikrein Inhibitor — BLOOD AND BLOOD FORMING ORGANS

Key facts

Lanadelumab is a drug in the Plasma Kallikrein Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2018. Its mechanism of action is classified as Kallikrein Inhibitors. DrugCentral lists 1 molecular target, including KLKB1. Recorded indications include Hereditary angioneurotic edema.

• Drug class: Plasma Kallikrein Inhibitor.
• Mechanism of action: Kallikrein Inhibitors.
• Molecular targets: KLKB1 (1 listed in DrugCentral).
• Indications: Hereditary angioneurotic edema.
• ATC code: B06AC05 (Drugs used in hereditary angioedema).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Hereditary angioneurotic edema

Mechanism & targets

• Mechanism of action (MoA): Kallikrein Inhibitors
• Established pharmacologic class: Plasma Kallikrein Inhibitor

Molecular targets (1)

Target	Gene	Action	Activity
Plasma kallikrein	KLKB1	other	IC50 10.05

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2022-03-28	PMDA	—	Takeda Pharmaceutical Company Limited	Yes
2018-11-22	EMA	—	SHIRE PHARMACEUTICALS IRELAND LTD	Yes
2018-08-23	FDA	—	DYAX CORP	Yes

ATC classification

ATC code	Therapeutic hierarchy
B06AC05	BLOOD AND BLOOD FORMING ORGANS › OTHER HEMATOLOGICAL AGENTS › OTHER HEMATOLOGICAL AGENTS › Drugs used in hereditary angioedema

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Hereditary angioedema	3588.3
Product dose omission issue	329.7
Inappropriate schedule of product administration	224.1
Insurance issue	216.4
Weight increased	194.7
Injection site pain	190.7
Pharyngeal swelling	158.5
Weight decreased	151.1
Product availability issue	138.4
No adverse event	97.1
Stress	79.7
COVID-19	75.6

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 1426055-14-2
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Lanadelumab used for?

DrugCentral lists the following indications for Lanadelumab: Hereditary angioneurotic edema.

How does Lanadelumab work?

Lanadelumab is classified as Kallikrein Inhibitors; its molecular targets in DrugCentral include KLKB1.

When was Lanadelumab first approved?

Lanadelumab was first approved by the FDA in 2018.

What drug class does Lanadelumab belong to?

Lanadelumab is in the Plasma Kallikrein Inhibitor class.

Sources

• DrugCentral drug card 5309 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3545189 — compound record and bioactivity
• DrugBank DB14597 — drug record
• FDA UNII 2372V1TKXK — substance identity
• DailyMed: FDA labels for Lanadelumab — current prescribing information (label search)
• UniProt P03952 (KLKB1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.